GATA15 Antibody
Description
GATA15 Protein Overview
GATA15 is a short B-GATA transcription factor (41 kDa) with two GATA-type zinc fingers. It regulates gene expression in response to cytokinin (CK) signaling and interacts with other LLM-domain B-GATAs (e.g., GATA16, GATA17, GATA17L) . Key functions include:
-
Phyllotactic Patterning: Controls leaf arrangement and floral organ positioning.
-
Meristem Development: Affects accessory meristem formation.
-
CK Signaling: Overlaps with GNC/GNL in CK-regulated processes like greening and senescence .
Antibody Development Challenges
While GATA15’s biological role is well-documented , no validated GATA15-specific antibody exists in public databases (e.g., JASPAR, PubMed). This gap reflects:
-
Sequence Similarity: GATA15 shares high homology with GATA16, GATA17, and GATA17L, complicating epitope selection .
-
Expression Patterns: Limited expression in specific tissues (e.g., developing organs) may hinder antibody validation .
-
Research Focus: Prioritization of GATA5/GATA3 antibodies in human oncology and immunology .
Table 2: GATA3 Antibody Performance in Breast Cancer Diagnosis
| Antibody Clone | Sensitivity | Specificity | Applications |
|---|---|---|---|
| L50-823 | 96% (non-TNBC) | 84% | IHC for breast CA identification |
| HG3-31 | 96% (non-TNBC) | 97% | IHC for breast CA identification |
GATA15’s DNA Binding Profile
GATA15’s DNA-binding specificity is characterized by position weight matrices (PWMs) in publicly available databases (e.g., JASPAR):
-
Matrix ID: MA1016.1
-
Family: C4-GATA-related
-
Species: Arabidopsis thaliana .
This profile guides epitope design for future antibody development.
Research Gaps and Future Directions
-
Antibody Development:
-
Functional Studies:
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
Clarification: The provided search results contain extensive information about GDF15 antibodies (PMC11341059) and GATA-family antibodies (GATA-2/3/5), but no references to "GATA15" were identified. Below are research-focused FAQs based on antibody development methodologies and validation strategies from the available data, structured to address both foundational and advanced research considerations.
What strategies resolve discrepancies in neutralizing antibody efficacy data?
Methodological Framework
Advanced Analysis:
-
Use reporter cell lines (e.g., HEK293 SER-Luc2-cRET-GFRAL ) to quantify target engagement kinetics.
-
Address dose-response paradoxes (e.g., fluorescence signal recovery at high GDF15 concentrations due to antibody saturation ).
How to optimize antibody humanization for therapeutic applications?
Basic Protocol:
Advanced Engineering:
-
Employ structure-guided mutagenesis to resolve manufacturability issues:
What controls are essential for intracellular staining of transcription factors?
Basic Requirements:
-
Fixation/permeabilization buffers validated for epitope retention (e.g., FlowX FoxP3 Kit )
-
Parallel staining with:
Advanced Pitfalls:
-
Cell cycle-dependent expression variations (GATA-2 levels fluctuate 2.5-fold during hematopoiesis )
-
Fixation artifacts causing false nuclear localization (validate with fractionation assays )
How to validate antibody performance across disease models?
Case Study – Cancer Cachexia :
-
Biological Relevance: Confirm target overexpression (GDF15 elevated 8x in cachectic patients)
-
Mechanistic Proof: Demonstrate GFRAL-RET pathway blockade via:
-
Phosphorylation assays (RET inhibition >80%)
-
Weight trajectory analysis (Δ= +12% vs. untreated)
-
-
Therapeutic Specificity: Exclude off-target appetite regulation (ghrelin/leptin pathways unaffected)
